Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CCCC

C4 Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CCCC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

C4 Therapeutics, Inc. (NASDAQ: CCCC) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:58 UTC.

What C4 Therapeutics, Inc. does

The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation, or TPD, technology using its proprietary TORPEDO platform to design small-molecule medicines that harness the body's natural protein destruction process. Its clinical pipeline includes cemsidomide, an oral degrader of IKZF1 and IKZF3 proteins for multiple myeloma, and CFT8919, an oral EGFR degrader for non-small-cell lung cancer being developed with partner Betta Pharma in Greater China.

Summarized from C4 Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-40.92%

Revenue, margins & earnings

FY2021: net loss $84M on revenue $46M$46MFY2021FY2022: net loss $128M on revenue $31M$31MFY2022FY2023: net loss $132M on revenue $21M$21MFY2023FY2024: net loss $105M on revenue $36M$36MFY2024FY2025: net loss $105M on revenue $36M$36MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02DirectorAward3,662$11.5K
  • 2026-10-02DirectorAward4,618$14.5K
  • 2026-09-21Chief Financial OfficerTax withholding-2,775$9.4K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does C4 Therapeutics, Inc. do?

The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation, or TPD, technology using its proprietary TORPEDO platform to design small-molecule medicines that harness the body's natural protein destruction process.

When did CCCC last file with the SEC?

C4 Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-24. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:58 UTC. This page is also available as JSON at /api/data?ticker=CCCC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CCCC and 5,000+ tickers.

Create a free account — keep CCCC
For your agent
GET /api/data?ticker=CCCC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt